Abiopharma

New Form EFFECT - ICAD INC Filed: 2025-07-21 AccNo: 9999999995-25-002289 Size: 1 KB

New Form EFFECT - ICAD INC Filed: 2025-07-21 AccNo: 9999999995-25-002290 Size: 1 KB

New Form EFFECT - ICAD INC Filed: 2025-07-21 AccNo: 9999999995-25-002291 Size: 1 KB

New Form EFFECT - ICAD INC Filed: 2025-07-21 AccNo: 9999999995-25-002292 Size: 1 KB

New Form EFFECT - SciSparc Ltd. Filed: 2025-07-21 AccNo: 9999999995-25-002296 Size: 1 KB

Westlake - Westlake Announces Second Quarter 2025 Earnings Conference Call

Westlake - Westlake Chemical Partners Announce Second Quarter 2025 Earnings Conference Call

Aurinia Pharmaceuticals to Release Second Quarter 2025 Financial and Operational Results on July 31, 2025

Westlake Announces Second Quarter 2025 Earnings Conference Call

General Announcement: CHANGES IN SUBSTANTIAL SHAREHOLDERS INTEREST PURSUANT TO SECTION 138 OF THE COMPANIES ACT 2016

WGS Investors Have Opportunity to Join GeneDx Holdings Corp. Investigation With the DJS Law Group

Takeda的HyHubTM和HyHubTM Duo裝置獲FDA 510(k)核准，簡化HYQVIA®給藥流程

Takeda的HyHubTM和HyHubTM Duo装置获FDA 510(k)批准，简化HYQVIA®给药流程

Takeda recibe la autorización 510(k) de la FDA para los dispositivos HyHubTM y HyHubTM Duo que simplifican la administración de HYQVIA®

Takeda recebe aprovação 510(k) da FDA para dispositivos HyHubTM e HyHubTM Duo, a fim de simplificar a administração de HYQVIA®